Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244516 · ClinicalTrials.gov registry record · NA
Multi-Center 2-Week Clinical Evaluation of Three Silicone Hydrogel Contact Lenses
A NA study, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 540
- Enrollment target
NCT01244516: Completed NA study, sponsored by Johnson & Johnson Vision Care.
NCT01244516 is a NA study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 540 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01244516, a NA study, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 540 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the clinical performance of three silicone hydrogel contact lenses over a 2 week period.
Primary Outcome
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Interventions
- DEVICE galyfilcon A, BC 8.30
- DEVICE lotrafilcon B, BC 8.60
- DEVICE comfilcon A, BC 8.60
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2010-09-01 |
| Est. Completion | 2010-11-01 |
| Phase | NA |
What the finished NCT01244516 record still lists
NCT01244516 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which galyfilcon A, BC 8.30 is the first listed.
NCT01244516 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01244516 about?
NCT01244516 is a clinical study titled "Multi-Center 2-Week Clinical Evaluation of Three Silicone Hydrogel Contact Lenses". The purpose of this study is to compare the clinical performance of three silicone hydrogel contact lenses over a 2 week period.
What is the current status of trial NCT01244516?
This trial is currently completed. It is a NA study. The enrollment target is 540 participants. The study started on 2010-09-01. Estimated completion is 2010-11-01.
What interventions are being tested in trial NCT01244516?
The interventions under investigation include: galyfilcon A, BC 8.30 (DEVICE), lotrafilcon B, BC 8.60 (DEVICE), comfilcon A, BC 8.60 (DEVICE).
Who is sponsoring clinical trial NCT01244516?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01244516's enrollment target sits among peer trials
540 187th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI